RBC Capital analyst Gregory Renza maintained a Buy rating on BELLUS Health (BLU – Research Report) yesterday and set a price target of $8.00. The company’s shares closed last Monday at $4.78, close to its 52-week high of $5.15.
According to TipRanks.com, Renza is a 1-star analyst with an average return of -2.2% and a 32.0% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Inovio Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $10.55 average price target, a 120.7% upside from current levels. In a report released yesterday, Research Capital also maintained a Buy rating on the stock with a C$11.10 price target.
The company has a one-year high of $5.15 and a one-year low of $2.01. Currently, BELLUS Health has an average volume of 1.03M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.